ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he noted, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.
You may also like...
ASCO Audio Journal of Oncology – June 1st, 2006 – In the company of Gordon McVie 30 May, 2006 For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival 28 Sep, 2009 GAVI Talks: New Funding Mechanisms Make Vaccines Affordable 21 Jun, 2011 Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer 16 Nov, 2007
- Previous story Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
- Next story Low risk localized prostate cancer: no harm from waiting!
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014